new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Incyte Corporation
Incyte Corporation A Delaware Corporation
Incyte Corporationn A Delaware Corporation

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Incyte Corporation patents


      
Recent patent applications related to Incyte Corporation. Incyte Corporation is listed as an Agent/Assignee. Note: Incyte Corporation may have other listings under different names/spellings. We're not affiliated with Incyte Corporation, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Incyte Corporation-related inventors




Search recent Press Releases: Incyte Corporation-related press releases
Count Application # Date Incyte Corporation patents (updated weekly) - BOOKMARK this page
12010002252201/28/10 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
22015023849208/27/15  new patent  Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
32015022537508/13/15 Cyclopropylamines as lsd1 inhibitors
42015022537908/13/15 Cyclopropylamines as lsd1 inhibitors
52015022539408/13/15 Cyclopropylamines as lsd1 inhibitors
62015022540108/13/15 Cyclopropylamines as lsd1 inhibitors
72015022541108/13/15 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
82015021817408/06/15 Processes for preparing jak inhibitors and related intermediate compounds
92015021069207/30/15 Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
102015019037807/09/15 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3- dioxygenase
112015018380507/02/15 Processes and intermediates for making a jak inhibitor
122015017560406/25/15 Tricyclic heterocycles as bet protein inhibitors
132015016490006/18/15 Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
142015014834205/28/15 Bicyclic heterocycles as bet protein inhibitors
152015014834805/28/15 Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
162015014837205/28/15 Bicyclic heterocycles as bet protein inhibitors
172015014837505/28/15 Bicyclic heterocycles as bet protein inhibitors
182015013367405/14/15 Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
192015008763203/26/15 Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as jak inhibitors
202015008766203/26/15 Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
212015006544703/05/15 Survival benefit in patients with solid tumors with elevated c-reactive protein levels
222015006548403/05/15 Sustained release dosage forms for a jak1 inhibitor
232015005726502/26/15 Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
242015002505601/22/15 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
252015001717301/15/15 Antibodies to human transmembrane proteins
262015001154001/08/15 Tricyclic heterocycles as bet protein inhibitors
272015000416501/01/15 Secreted proteins
282014037729212/25/14 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
292014037840012/25/14 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
302014037121612/18/14 Purinone derivatives as hm74a agonists
312014034303011/20/14 Bipyrazole derivatives as jak inhibitors
322014031596210/23/14 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3- dioxygenase
332014027503009/18/14 Tricyclic heterocycles as bet protein inhibitors
342014027503109/18/14 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
352014027512709/18/14 Substituted heteroaryl fused derivatives as pi3k inhibitors
362014025694109/11/14 Processes and intermediates for making a jak inhibitor
372014024913209/04/14 Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
382014024208608/28/14 Polynucleotides encoding signal peptide-containing molecules
392014024330808/28/14 Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
402014024336008/28/14 Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
412014022727508/14/14 Methods of treating and diagnosing pancreatitis
422014022727808/14/14 Antibodies to human signal peptide-containing proteins
432014022834608/14/14 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
442014022137908/07/14 N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
452014020021607/17/14 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
462014020022707/17/14 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
472014018753007/03/14 Aza spiro alkane derivatives as inhibitors of metalloproteases
482014017140506/19/14 Fused pyrazoles as fgfr inhibitors
492014017140906/19/14 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
502014015528806/05/14 Methods for diagnosing cancer
512014015537706/05/14 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
522014015540406/05/14 Piperazinylpiperidine derivatives as chemokine receptor antagonists
532014013535005/15/14 Sustained-release dosage forms of ruxolitinib
542014012119805/01/14 Tricyclic fused thiophene derivatives as jak inhibitors
552014012122205/01/14 Pyrimidinones as pi3k inhibitors
562014006644803/06/14 Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
572014005690602/27/14 Secreted proteins
582014005791202/27/14 Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
592014004581402/13/14 Pyrazine derivatives as fgfr inhibitors
602014003134401/30/14 Azepine inhibitors of janus kinases
612014002366301/23/14 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
622014001837401/16/14 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
632014000516601/02/14 Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
642014000521001/02/14 Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
652013034515712/26/13 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
662013034522412/26/13 Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
672013032451512/05/13 Imidazotriazines and imidazopyrimidines as kinase inhibitors
682013025319009/26/13 Processes for preparing jak inhibitors and related intermediate compounds
692013025319109/26/13 Processes for preparing jak inhibitors and related intermediate compounds
702013025319309/26/13 Processes for preparing jak inhibitors and related intermediate compounds
712013024378109/19/13 Signal peptide-containing proteins
722013024492709/19/13 Polynucleotides encoding signal peptide-containing molecules
732013024499909/19/13 Substituted heterocyclic compounds
742013022476908/29/13 Methods of using chemokine panec-1 antibodies
752013022555608/29/13 Azetidine and cyclobutane derivatives as jak inhibitors
762013019025007/25/13 Polynucleotides encoding human signal peptide-containing proteins
772013017759007/11/13 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
782013013768105/30/13 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
792013012324605/16/13 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
802013011623005/09/13 3-aminopyrrolidine derivatives as modulators of chemokine receptors
812013009614404/18/13 Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors
822013005894203/07/13 Human beta-adrenergic receptor kinase polypeptide and methods
832013005983503/07/13 Heterocyclylamines as pi3k inhibitors
842013006002603/07/13 Processes and intermediates for making a jak inhibitor
852013004596302/21/13 Cyclohexyl azetidine derivatives as jak inhibitors
862013001803401/17/13 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
872013001806801/17/13 Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
882012032978212/27/12 Azepine inhibitors of janus kinases
892012030146411/29/12 Janus kinase inhibitors for treatment of dry eye and other eye related diseases
902012029591211/22/12 Piperazinylpiperidine derivatives as chemokine receptor antagonists
912012027080910/25/12 Human transmembrane proteins
922012012285805/17/12 Lactam compounds and their use as pharmaceuticals
932012004096402/16/12 N-substituted piperidines and their use as pharmaceuticals
942012003517202/09/12 Purinone derivatives as hm74a agonists
952012001493701/19/12 Human beta-adrenergic receptor kinase polypeptide and methods
962012001592801/19/12 Amido compounds and their use as pharmaceuticals
972011025121510/13/11 Macrocyclic compounds and their use as kinase inhibitors
982011021296709/01/11 Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
992011020775408/25/11 Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
1002011013678106/09/11 Imidazotriazines and imidazopyrimidines as kinase inhibitors
1012011008681004/14/11 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
1022011008215904/07/11 Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
1032011005321703/03/11 Polynucleotides encoding signal peptide-containing molecules
1042010027933311/04/10 Methods of treatment with antibodies to a chemokine expressed in inflamed adenoid
1052010025611410/07/10 Amido compounds and their use as pharmaceuticals
1062010024067109/23/10 Substituted heterocyclic compounds
1072010020303908/12/10 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
1082010019080407/29/10 Macrocyclic compounds and their use as kinase inhibitors
1092010017390107/08/10 Substituted heterocyclic compounds
1102010013740106/03/10 2-methylprop anamides and their use as pharmaceuticals
1112010011950305/13/10 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
1122010009961704/22/10 Secreted proteins
1132009031840512/24/09 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
1142009029194611/26/09 Lactam compounds and their use as pharmaceuticals
1152009028677411/19/09 Purinone derivatives as hm74a agonists
1162009028677811/19/09 Macrocyclic compounds and their use as kinase inhibitors
1172009027468011/05/09 Human phospholipases
1182009023390309/17/09 Azetidine and cyclobutane derivatives as jak inhibitors
1192009021576608/27/09 Tetracyclic inhibitors of janus kinases
1202009019788708/06/09 Piperazinylpiperidine derivatives as chemokine receptor antagonists
1212009018195907/16/09 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1222009012464905/14/09 Aza spiro alkane derivatives as inhibitors of metalloproteases
1232009008844604/02/09 Purinone derivatives as hm74a agonists
1242009007626903/19/09 Purinone derivatives as hm74a agonists
1252012026367610/18/12 Compositions, methods and kits relating to her-2 cleavage
1262012005807903/08/12 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
1272012001498901/19/12 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
1282011031147912/22/11 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
1292011022321009/15/11 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1302011022415709/15/11 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1312011017227907/14/11 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1322011016518807/07/11 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1332011008683504/14/11 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
1342009029880812/03/09 Inhibitors of 11-beta hydroxyl steroid dehydrogenase type i and methods of using the same
1352009019786908/06/09 Azepine inhibitors of janus kinases



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Incyte Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Incyte Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE